Cutaneous Oncology

Top Story

T-VEC, ipilimumab regimen improves survival in advanced melanoma

T-VEC, ipilimumab regimen improves survival in advanced melanoma
November 10, 2017

The combination of an oncolytic virus plus a checkpoint inhibitor improved survival among patients with advanced melanoma compared with monotherapy, according to data from a phase 2 study published in Journal of Clinical Oncology.

Novel monotherapies, such as ipilimumab (Yervoy, Bristol-Myers Squibb) — a CTLA-4 antibody — have “transformed patient care in advanced melanoma,” the researchers wrote.

In the Journals

Immunosuppression in multiple myeloma may not increase melanoma risk

November 3, 2017
Although immunosuppression associated with multiple myeloma may not predispose patients to melanoma, other immunosuppressed states may increase melanoma risk, according…
In the Journals

Compliance with tanning bed regulations remains unsatisfactory

October 30, 2017
Compliance with state laws surrounding use of indoor tanning beds among minors remains unsatisfactory, according to research published in JAMA Dermatology. The…
In the Journals

Education increased sunscreen use among student athletes

October 26, 2017
An educational intervention targeting sunscreen use in student athletes was associated with improved sunscreen use. Researchers with the Stanford University Network for…
More Headlines »
Advertisement
Advertisement